How to titrate basal (basal insulin) bolus (bolus insulin) insulin, specifically glargine (insulin glargine) and aspart (insulin aspart), in hospitalized patients with type 2 diabetes mellitus (T2DM) who are eating orally?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Basal-Bolus Insulin Titration in Hospitalized Patients Eating Orally

Initial Dosing Strategy

For hospitalized patients with type 2 diabetes eating regular meals, start with a total daily dose of 0.5 units/kg/day, divided as 50% basal insulin (glargine once daily) and 50% bolus insulin (aspart divided equally before three meals). 1, 2

  • For a 70 kg patient, this translates to approximately 35 units total daily: 17-18 units glargine once daily and 5-6 units aspart before each meal 2
  • Reduce the starting dose to 0.3 units/kg/day for patients at high risk of hypoglycemia (elderly >65 years, renal impairment, thin/frail patients) 1, 3
  • For patients on high-dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20% upon admission 3

Daily Titration Algorithm

Adjusting Basal Insulin (Glargine)

Titrate glargine every 3 days based on fasting glucose patterns:

  • If fasting glucose is 140-179 mg/dL: increase by 2 units 1, 3
  • If fasting glucose is ≥180 mg/dL: increase by 4 units 1, 3
  • If fasting glucose is <80 mg/dL on more than 2 occasions per week: decrease by 2 units 3
  • Target fasting glucose: 80-130 mg/dL 1

Adjusting Bolus Insulin (Aspart)

Titrate aspart every 3 days based on 2-hour postprandial glucose readings:

  • Increase by 1-2 units (or 10-15%) if postprandial glucose consistently >180 mg/dL 1, 3
  • Decrease by 10-20% if hypoglycemia occurs without clear cause 1, 3
  • Target postprandial glucose: <180 mg/dL 1

Four-Day Titration Example

Day 1 (Admission)

Patient: 70 kg, eating regular meals, no prior insulin

  • Starting doses: Glargine 17 units at bedtime, aspart 6 units before each meal
  • Pre-breakfast: 220 mg/dL → Give 6 units aspart
  • 2h post-breakfast: 240 mg/dL
  • Pre-lunch: 200 mg/dL → Give 6 units aspart
  • 2h post-lunch: 230 mg/dL
  • Pre-dinner: 190 mg/dL → Give 6 units aspart
  • 2h post-dinner: 210 mg/dL
  • Bedtime: Give 17 units glargine

Day 2

Analysis: Fasting glucose ≥180 mg/dL, all postprandial values >180 mg/dL

  • Adjustments: Increase glargine by 4 units to 21 units; increase each aspart dose by 2 units to 8 units
  • Pre-breakfast: 210 mg/dL → Give 8 units aspart
  • 2h post-breakfast: 200 mg/dL
  • Pre-lunch: 180 mg/dL → Give 8 units aspart
  • 2h post-lunch: 190 mg/dL
  • Pre-dinner: 170 mg/dL → Give 8 units aspart
  • 2h post-dinner: 180 mg/dL
  • Bedtime: Give 21 units glargine

Day 3

Analysis: Fasting glucose still ≥180 mg/dL, postprandial values improving but still elevated

  • Adjustments: Increase glargine by 4 units to 25 units; increase breakfast and lunch aspart by 1 unit each to 9 units
  • Pre-breakfast: 195 mg/dL → Give 9 units aspart
  • 2h post-breakfast: 170 mg/dL
  • Pre-lunch: 160 mg/dL → Give 9 units aspart
  • 2h post-lunch: 165 mg/dL
  • Pre-dinner: 155 mg/dL → Give 8 units aspart
  • 2h post-dinner: 160 mg/dL
  • Bedtime: Give 25 units glargine

Day 4

Analysis: Fasting glucose 180 mg/dL (borderline), postprandial values approaching target

  • Adjustments: Increase glargine by 2 units to 27 units (using 2-unit increment since approaching target); maintain aspart doses
  • Pre-breakfast: 180 mg/dL → Give 9 units aspart
  • 2h post-breakfast: 155 mg/dL
  • Pre-lunch: 145 mg/dL → Give 9 units aspart
  • 2h post-lunch: 150 mg/dL
  • Pre-dinner: 140 mg/dL → Give 8 units aspart
  • 2h post-dinner: 155 mg/dL
  • Bedtime: Give 27 units glargine

Critical Monitoring Points

Check point-of-care glucose before each meal and at bedtime (4 times daily) for patients eating regular meals. 1

  • For patients with poor oral intake, check glucose every 4-6 hours 1
  • Target glucose range for non-critically ill hospitalized patients: 140-180 mg/dL 1

Essential Pitfalls to Avoid

Never use sliding scale insulin as monotherapy—it is explicitly condemned by all major guidelines and leads to dangerous glucose fluctuations. 1, 4

  • Do not wait for "stable patterns" before adjusting doses—adjust daily based on glucose trends 3
  • Avoid giving rapid-acting insulin at bedtime, as this increases nocturnal hypoglycemia risk 1, 3
  • Do not continue full home insulin doses in patients with decreased oral intake—reduce by 50% to prevent severe hypoglycemia 1, 5, 6
  • Never mix or dilute glargine with other insulins due to its low pH 7, 8

Special Considerations for Poor Oral Intake

If oral intake decreases during hospitalization, immediately reduce total daily insulin to 0.1-0.15 units/kg/day given primarily as basal insulin, with correctional aspart only for glucose >180 mg/dL. 1, 5

  • This represents approximately a 50% dose reduction from standard basal-bolus dosing 5
  • Continue basal insulin coverage even with minimal intake—do not rely solely on correction doses 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin management of diabetic patients on general medical and surgical floors.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2006

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Insulin management of type 2 diabetes mellitus.

American family physician, 2011

Guideline

Insulin Glargine Management in Patients with Decreased Oral Intake

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

EADSG Guidelines: Insulin Therapy in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

Related Questions

How do I incorporate correction doses using the insulin sensitivity factor into a basal-bolus insulin regimen for a 70 kg patient with type 2 diabetes mellitus (T2DM) who is eating orally?
What is the recommended initial dosing regimen for a patient with diabetes who requires twice-daily (2 times a day) insulin dosing, specifically using NPH (Neutral Protamine Hagedorn) insulin?
What is the best way to adjust insulin for an adult patient with type 2 diabetes mellitus (T2DM) requiring insulin regimen modification?
Can I start a patient with a hemoglobin A1c (HbA1c) level of 16.1% on 20 units of basal insulin if they are already on metformin (Metformin) 500 mg extended release (ER)?
What are the recommended treatment regimens for type 1 and type 2 diabetes?
What is the recommended treatment approach for a patient diagnosed with Rhabdomyosarcoma?
Can olanzapine (atypical antipsychotic) cause hyponatremia, especially in older adults or those with impaired renal function?
What lab test is used to monitor a patient on warfarin (anticoagulant)?
What are the indications and considerations for amniocentesis in pregnant individuals, particularly those of advanced maternal age (over 35 years) or with a family history of genetic disorders?
What is the appropriate management for a 3-year-old child presenting with a macular rash on the face and arms, without pruritus or signs of infection, and with possible exposure to cold, in the absence of known allergies?
What is the best approach to manage a adult patient with a history of heart failure with reduced ejection fraction (HFrEF) who is currently on lisinopril (angiotensin-converting enzyme inhibitor) 2.5 mg daily, torsemide (loop diuretic) 40 mg daily, and carvedilol (beta blocker) 25 mg twice a day?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.